Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Politics, Policy & Law

Christie’s COVID-19 treatment raises fairness, safety questions

October 16, 2020 3:48 PM UTC

Former New Jersey Gov. Chris Christie’s treatment for COVID-19 raises questions about the fairness of decisions to grant access to investigational therapies, as well as the safety of exposing patients to untested drug combinations.

Instead of being treated with a mAb product from  Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) that is being tested at the facility where he was hospitalized, Christie received a mAb cocktail that Eli Lilly and Co. (NYSE:LLY) is testing in COVID-19 patients who have less severe symptoms. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article